Correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with prognosis in gastric cancer patients undergoing neoadjuvant chemotherapy: a meta-analysis
- PMID: 40597685
- PMCID: PMC12211959
- DOI: 10.1186/s12876-025-04056-x
Correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with prognosis in gastric cancer patients undergoing neoadjuvant chemotherapy: a meta-analysis
Abstract
Introduction: Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are associated with poorer prognosis of gastric cancer (GC) patients and may guide treatment decisions. This meta-analysis aims to evaluate the impact of NLR and PLR on the prognosis of GC patients undergoing neoadjuvant chemotherapy (NAC).
Methods: Cochrane, Embase, PubMed and Web of science were searched for studies up to November 30, 2024. Meta-analysis was conducted to evaluate the pooled effect. Sensitivity analysis was conducted by removing a different study each time. Publication bias was assessed by Egger’s test and Begg’s test to evaluate quantitatively.
Results: A total of 16 studies were included in this meta-analysis from 3,094 studies. Pre-NAC high NLR level was associated with poorer overall survival outcomes (HR = 1.96, 95% CI 1.21–3.20). Similarly, post-NAC high NLR was also correlated with worse overall survival outcomes (HR = 1.69, 95% CI 1.04–2.76). However, pre-NAC PLR and post-NAC PLR did not appear to exhibit a significant correlation with the prognosis of gastric cancer patients following NAC.
Conclusion: NLR is emerging as a potential prognostic indicator for gastric cancer, particularly in patients receiving NAC. Elevated NLR levels both before and after NAC are associated with poorer overall survival outcomes in gastric cancer patients.
Supplementary Information: The online version contains supplementary material available at 10.1186/s12876-025-04056-x.
Keywords: Gastric cancer; Meta-analysis; Neoadjuvant chemotherapy; Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Our study was conducted in strict accordance with the relevant provisions of the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Similar articles
-
Prognostic role of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte, and lymphocyte-to-monocyte ratio in operated rectal cancer patients: systematic review and meta-analysis.Langenbecks Arch Surg. 2023 Feb 13;408(1):85. doi: 10.1007/s00423-023-02786-8. Langenbecks Arch Surg. 2023. PMID: 36781510
-
Tumor-Infiltrating Lymphocytes Demonstrate Distinct Behavior in the Tumoral and Peritumoral Microenvironment After Neoadjuvant Chemotherapy in Patients with Resected Adenocarcinoma of the Gastric or Gastroesophageal Junction: Results from a Single Center.Cancers (Basel). 2025 Jun 13;17(12):1971. doi: 10.3390/cancers17121971. Cancers (Basel). 2025. PMID: 40563621 Free PMC article.
-
Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis.Ann Surg Oncol. 2016 Feb;23(2):646-54. doi: 10.1245/s10434-015-4869-5. Epub 2015 Sep 28. Ann Surg Oncol. 2016. PMID: 26416715
-
Exploring the association between hemoglobin, hematocrit, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with erectile dysfunction in chronic kidney disease patients undergoing hemodialysis: a cross-sectional study.Arch Ital Urol Androl. 2025 Jun 30;97(2):13856. doi: 10.4081/aiua.2025.13856. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583617
-
Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer.J Immunother Cancer. 2025 Jun 24;13(6):e011458. doi: 10.1136/jitc-2025-011458. J Immunother Cancer. 2025. PMID: 40555561 Free PMC article.
References
-
- De Vita F, Giuliani F, Silvestris N, Rossetti S, Pizzolorusso A, Santabarbara G, Galizia G, Colucci G, Ciardiello F, Orditura M. Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets. 2012;16(Suppl 2):S29–34. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous